A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

Clinical trial NCT07637578 · RECRUITING

Trial details

NCT number: NCT07637578
Sponsor: SCRI Development Innovations, LLC
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma (MM)Multiple Myeloma Refractory Multiple Myeloma in Relapse Multiple Myeloma

Start date: 2026-08-01
Primary completion: 2029-10-01
Enrollment: 46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.